Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Trevi Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 77 | 1 | 93 | +17 |
| Shares | 55.9M | 3.14M | 58.1M | +5.35M (+10.1%) |
| Value | $166.6M | $9.34M | $194.1M | +$36.9M (+23.4%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Trevi Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 3,221,752 | $10.8M | 0.00% |
| Vivo Capital, LLC | 1,612,903 | $5.39M | 0.45% |
| Woodline Partners LP | 606,227 | $2.02M | 0.02% |
| Gsa Capital Partners LLP | 122,447 | $409.0K | 0.03% |
| Marshall Wace, LLP | 81,124 | $271.0K | 0.00% |
| Fred Alger Management, LLC | 76,544 | $255.7K | 0.00% |
| Hudson Bay Capital Management LP | 50,000 | $167.0K | 0.00% |
| Citadel Advisors LLC | 49,881 | $166.6K | 0.00% |
| Susquehanna International Group, LLP | 40,378 | $134.9K | 0.00% |
| Panagora Asset Management Inc | 24,901 | $83.2K | 0.00% |
| Algert Global LLC | 24,589 | $82.1K | 0.00% |
| SG Americas Securities, LLC | 23,405 | $78.0K | 0.00% |
| Millennium Management LLC | 20,621 | $68.9K | 0.00% |
| Intech Investment Management LLC | 18,914 | $63.2K | 0.00% |
| AJOVista, LLC | 11,495 | $38.4K | 0.16% |
| ProShare Advisors LLC | 11,096 | $37.1K | 0.00% |
| Simplex Trading, LLC | 9,641 | $32.0K | 0.00% |
| Capital Performance Advisors LLP | 134 | $448 | 0.00% |
| Sterling Capital Management LLC | 109 | $364 | 0.00% |
Sold out (2)
Institutions that held Trevi Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Propel Bio Management, LLC | 260,000 | $774.8K |
| Simplify Asset Management Inc. | 200,000 | $596.0K |
Not filed for Q3 2024 yet (1)
Institutions that held Trevi Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 3,135,115 | $9.34M |